Navigation Links
ViroPharma Announces Initiation of Phase 2 Evaluation of Subcutaneous Delivery of Cinryze(TM) (C1 Esterase Inhibitor [Human])
Date:4/27/2010

EXTON, Pa., April 27 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that it has initiated an open-label, multi-dose Phase 2 study to evaluate the safety, and pharmacokinetics and pharmacodynamics of subcutaneous versus intravenous administration of Cinryze™ (C1 esterase inhibitor [human)] in 24 adolescents and adult subjects with hereditary angioedema (HAE).  Cinryze was approved by the U.S. Food and Drug Administration in October 2008 for routine prophylaxis against angioedema attacks in adolescent and adult patients with HAE.

"The experience with intravenous delivery of Cinryze has been exceptional, with many patients taking advantage of our unique labeling option of self-administration and dosing themselves in their homes or wherever their schedule takes them," commented Judy Johnson, ViroPharma's vice president of clinical pharmacology and non-clinical development. "Based on encouraging data from a previous single-dose Phase 1 study in healthy subjects, we believe that subcutaneous administration of Cinryze may become a viable alternative mode of administration for routine prophylaxis of HAE attacks."

Clinical Study Design

This multi-center, open-label multiple dose study will be conducted in 24 adolescent and adult HAE patients in the US and Europe. All eligible subjects will be randomized into one of two treatment groups:  Patients will receive Cinryze via IV infusion two times per week for two weeks.  Then, following a 14-day washout period, patients will receive Cinryze via subcutaneous administration at one of two dose lev
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology news :

1. Selexis Announces Advanced Approach to Maximize Power of Genetic Elements for Rapid Development of High Performance Cell Lines
2. LaserCard Corporation Announces Expansion of Middle East Project
3. BIO-key(R) Announces Contracts for New Criminal Justice Data Sharing Solution
4. Balzan Foundation announces 2007 winners
5. The American Society of Plant Biologists announces 2007 awards
6. ASPB announces Summer Undergraduate Research Fellowship 2007 recipients
7. NIST announces 56 new awards for innovative technology research and development
8. Titanium Group Announces Contract With Haitong Securities
9. Measurement Specialties, Inc. Announces Impact of German Business Tax Reform 2008 Resulting in Lower Combined German Tax Rate - Impacts 2Q08 Reported Financial Results
10. FIJI Water announces sustainable growth initiative with commitment to help mitigate climate change
11. HGS announces positive Phase 2 LymphoStat-B at ACR meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... MARC (Maximizing Access to Research Careers) Program has announced ... Human Genetics from October 18 22, 2014 in ... promote the entry of students, post doctorates and scientists ... science community and to encourage the participation of young ... This year MARC conferred 16 awards totaling $29,600., The ...
(Date:8/28/2014)... identified the developmental on-off switch for Streptomyces , ... two-thirds of the world,s naturally derived antibiotic medicines. ... it is possible to manipulate this switch to make ... appearing August 28 in Cell , found that ... and a larger protein called BldD ultimately controls whether ...
(Date:8/28/2014)... measuring and imaging how quickly blood flows in the ... drug abuse affects the brain, which may aid in ... better treatment options for recovering drug addicts. The new ... Brook University in New York, USA and the U.S. ... Optical Society,s (OSA) open-access journal Biomedical Optics ...
Breaking Biology News(10 mins):Small molecule acts as on-off switch for nature's antibiotic factory 2Small molecule acts as on-off switch for nature's antibiotic factory 3This is your brain's blood vessels on drugs 2This is your brain's blood vessels on drugs 3
... in Temple University,s College of Science and Technology has ... leptin receptor antagonist peptide, developed by researchers Laszlo Otvos ... triple negative breast cancer treatment, especially in the obese ... in the European Journal of Cancer . ...
... developed a novel method for eavesdropping on terahertz ... doctoral student at Rensselaer Polytechnic Institute has demonstrated ... boost the distance from which researchers can use ... chemicals, and other dangerous materials. Clough, ...
... the answer to how and why primates differ from other ... the repetitive stretches of the genome that were once considered ... of Iowa Carver College of Medicine finds that when a ... element, is inserted into existing genes, they can alter the ...
Cached Biology News:New peptide could be effective treatment for triple negative breast cancer 2Student innovation at Rensselaer holds key to safer remote detection of dangerous materials 2Student innovation at Rensselaer holds key to safer remote detection of dangerous materials 3U. Iowa team investigates function of 'junk DNA' in human genes 2U. Iowa team investigates function of 'junk DNA' in human genes 3
(Date:8/29/2014)... Albany, New York (PRWEB) August 29, 2014 ... be valued at $5.6 billion in 2019. It ... 18.1% from 2013 to 2019, and was valued ... research report published by Transparency Market Research. , ... please visit: http://www.transparencymarketresearch.com/companion-diagnostics-market.html . , The research ...
(Date:8/29/2014)... PA (PRWEB) August 29, 2014 Pittcon ... Hub MacDonald, and colleague Koichiro Matsuda, Horiba Scientific, have ... on September 5, 2014. JASIS , Asia’s largest ... 3-5, 2014, in Makuhari Messe, Japan. , The ... Tools for Bioanalysis from Single Molecules to Single Cells” ...
(Date:8/29/2014)... Local veterinarian, Dr. Keith Clement, and his ... to participate in an investigational study of donor stem ... of this study is to determine if a single ... arthritically affected joints can help reduce pain and inflammation ... current investigational study must be older than nine months, ...
(Date:8/29/2014)... 29, 2014 Due to a misstatement posted ... the Adult Stem Cell Technology Center, LLC ( ASCTC ) ... cell therapy research that might benefit ALS patients. Because ... new stem cell technologies and therapeutic applications, FRC listed ASCTC ... Challenge donors who wish not to support research that ...
Breaking Biology Technology:Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 2Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 3Fifth Annual U.S. Symposium at JASIS Organized by Pittcon’s Program Chairman Hub MacDonald 2Burnt Hills Veterinary Hospital Seeks Candidates for an Investigational Study of Stem Cells for Dogs with Arthritis 2The Adult Stem Cell Technology Center, LLC Declines ALS Ice Bucket Challenge Donors Wishing to Support Ethical Research for New Stem Cell Therapies 2The Adult Stem Cell Technology Center, LLC Declines ALS Ice Bucket Challenge Donors Wishing to Support Ethical Research for New Stem Cell Therapies 3
... SAN FRANCISCO, Jan. 10, 2011 Enobia Pharma Inc., ... II study of ENB-0040, a bone targeted enzyme replacement ... serious, rare metabolic bone disorder. The results were presented ... of Enobia, at the 29th Annual J.P. Morgan Healthcare ...
... (Nasdaq: PRXL ) will release Second Quarter Fiscal ... the close of the stock market.  The announcement will be ... the PR Newswire website at www.prnewswire.com . ... 10:00 a.m. EST on Tuesday, February 1, 2011 to discuss ...
... DuPont (NYSE: DD ) has entered ... a global enzyme and specialty food ingredients company, for ... of Danisco net debt.  Upon closing, this transaction would ... with science-intensive innovations that address global challenges in food ...
Cached Biology Technology:Enobia Announces Successful Completion of Phase II Juvenile Study of ENB-0040, a Bone Targeted Enzyme Replacement Therapy 2Enobia Announces Successful Completion of Phase II Juvenile Study of ENB-0040, a Bone Targeted Enzyme Replacement Therapy 3PAREXEL Announces Date of Second Quarter Fiscal Year 2011 Earnings Release and Conference Call 2DuPont to Acquire Danisco for $6.3 Billion 2DuPont to Acquire Danisco for $6.3 Billion 3DuPont to Acquire Danisco for $6.3 Billion 4
... conserved form of cell suicide, which follows ... component of this process is a cascade ... enzymes participate in a series of reactions ... signals and result in the cleavage of ...
... System provides optimized reagents and protocols for ... genes by insertion of group II introns. ... group II introns and utilizes a simple ... II intron for specific insertion into the ...
Mouse monoclonal antibody raised against a full length recombinant PPIL2. NCBI Entrez Gene ID = PPIL2...
Mouse monoclonal antibody raised against a partial recombinant QARS. NCBI Entrez Gene ID = QARS...
Biology Products: